Navigation Links
AMDL ELISA DR-70(R) (FDP) is Promising as Effective Cancer Detection Test
Date:7/14/2008

TUSTIN, Calif., July 14 /PRNewswire-FirstCall/ -- (http://www.amdl.com) AMDL, Inc., (Amex: ADL) a leading vertically integrated bio-pharmaceutical company with major operations in China and the US, announced that the AMDL-ELISA DR- 70(R) (FDP) test has been shown to be a useful test for the detection of cancer in clinical practice according to an independent study of 185 patients from the Medical Department II at the University Hospital in Frankfurt Germany. The results were published in the international medical research publication Alimentary Pharmacology & Therapeutics.

The purpose of this independent study was to evaluate the potential of the DR-70 ELISA (FDP) test as a detection test for gastrointestinal cancers that include, colorectal, esophageal, gallbladder, gastric, liver, pancreatic and intestinal cancers. Additionally, the quantitative value of DR-70 (FDP) was tested as a parameter for the progression of these cancers. Serum samples were taken from a total of 80 cancer patients with histologically proven malignant tumors and 100 healthy blood donors in this study. Patients with colorectal cancer were also tested for carcinoembryogenic antigen (CEA), a competing diagnostic test to AMDL-ELISA DR-70 (FDP). The complete article about AMDL-ELISA DR-70 (FDP) can be accessed via AMDL's corporate website located at http://www.amdl.com under the RESOURCES link.

"When we compared the DR-70 immunoassay with conventional tumor markers, DR-70 turned out to be superior to CEA in the detection of patients with colorectal cancer," according to the conclusion of authors. The authors also concluded that DR-70 (FDP) levels were shown to be significantly higher across all types of gastrointestinal cancers tested and not limited to specific tumor types, suggesting the AMDL-ELISA DR-70 (FDP) test could be clinically used as a global cancer detection tool.

According to the results:

-- The AMDL-ELISA DR-70 (FDP) test showed strong clinical performance

with a sensitivity of 91% and a specificity of 93% in testing

conducted on patients with hepatocellular, cholangiocellular,

pancreatic, colorectal, stomach and oesophagus cancers.

-- The test reliably differs between patients with cancer of the

gastrointestinal tract or the hepatobilary system and healthy

patients; therefore showing promise as a useful cancer detection tool

in clinical practice.

-- The study also found an association between the quantitative DR-70

value and the stage of the cancer in patients tested which suggests

the AMDL-ELISA DR-70 (FDP) test can also be used as a prognostic

factor in cancer monitoring.

About AMDL: Headquartered in Tustin, CA with operations in Shenzhen, Jiangxi, and Jilin, China, AMDL, Inc., along with its subsidiary Jade Pharmaceutical Inc. (JPI), is a vertically integrated bio-pharmaceutical company devoted to the research, development, manufacturing, and marketing of diagnostic, pharmaceutical, nutritional supplement, and cosmetic products. The company employs approximately 320 people in the U.S. and China. The AMDL ELISA DR-70 (FDP) cancer diagnostic test was cleared to market by the US FDA on July 13, 2008 and the Company has 4 additional pharmaceutical and diagnostic products under review by various regulatory authorities. For additional information on AMDL and its products visit the company's website at http://www.amdl.com or call +1 (714)505-4460.

AMDL Contact:

Kristine Szarkowitz

Director-Investor Relations

kszarkowitz@amdl.com

(M) (206) 310-5323

(O) (206) 201-3286


'/>"/>
SOURCE AMDL, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. AMDL Submits Data to FDA for Clearance to Market Its DR-70(R) Diagnostic Test to Monitor Colorectal Cancer Patients
2. Amylin Pharmaceuticals to Present Promising Data From Diabetes and Obesity Programs at ADA 2008
3. Peregrine Pharmaceuticals Presents Promising Phase I Data at ASCO and Provides Clinical Update on Its Phase II Bavituximab Breast Cancer Study
4. Victhom announces promising results on the proof of concept for its unique closed-loop neuromodulation system
5. Transgenes Therapeutic Vaccine TG4010 Shows Promising Preliminary Phase IIb Data in Advanced Non-Small Cell Lung Cancer
6. Promising Data ATIR Studies Presented by NIH Investigators
7. Drugs from Johnson & Johnson/Basilea and Forest Are the Most Promising Antibiotics in the Community-Acquired Pneumonia Pipeline
8. Follow-up Phone Surveys: Effective Customer Service Assessment Tool for Improving Satisfaction
9. SciQuest Announces Newest Life Sciences Customer; BioMarin Pharmaceutical Drives Spending Effectiveness with Automated, Intuitive Procurement
10. Mega-Brand Success: Effective Market Strategy and Tactics
11. New VeriEye SDK from Neurotechnology Enables Development of Reliable, Cost-effective Biometric Iris Recognition Systems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a ... eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical research ... by providing practical tips, tools, and strategies for clinical researchers. , “The landscape ...
(Date:6/23/2016)... Md. , June 23, 2016 A person ... from the crime scene to track the criminal down. ... the U.S. Food and Drug Administration (FDA) uses DNA evidence ... Sound far-fetched? It,s not. The FDA ... sequencing to support investigations of foodborne illnesses. Put as simply ...
(Date:6/23/2016)... 23, 2016  The Biodesign Challenge (BDC), a university ... to harness living systems and biotechnology, announced its winning ... New York City . ... showcased projects at MoMA,s Celeste Bartos Theater during the ... MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... Durham, NC (PRWEB) , ... June 23, 2016 , ... ... Odense University Hospital in Denmark detail how a patient who developed lymphedema after being ... (fat) tissue. The results could change the paradigm for dealing with this debilitating, frequent ...
Breaking Biology Technology:
(Date:6/9/2016)... Paris Police Prefecture and ... ensure the safety of people and operations in several locations ... Teleste, an international technology group specialised in broadband ... its video security solution will be utilised by ... across the country. The system roll-out is scheduled for the ...
(Date:6/2/2016)... 2, 2016 Perimeter Surveillance & ... Systems, Physical Infrastructure, Support & Other Service  ... offers comprehensive analysis of the global Border ... generate revenues of $17.98 billion in 2016. ... a leader in software and hardware technologies for advanced ...
(Date:5/12/2016)... -- WearablesResearch.com , a brand of Troubadour Research ... the Q1 wave of its quarterly wearables survey. A ... to a program where they would receive discounts for ... "We were surprised to see that so ... , CEO of Troubadour Research, "primarily because there are ...
Breaking Biology News(10 mins):